CO-CRYSTALS OF ACTIVE PHARMACEUTICAL INGREDIENT-IBUPROFEN LYSINE

  • ALPANA KULKARNI Department of Pharmaceutics, MAEER’S Maharashtra Institute of Pharmacy, S. No. 124, MIT Campus, Paud Road, Kothrud, Pune 411038, Maharashtra, India
  • RITESH BACHHAV Department of Pharmaceutics, MAEER’S Maharashtra Institute of Pharmacy, S. No. 124, MIT Campus, Paud Road, Kothrud, Pune 411038, Maharashtra, India
  • VISHAL HOL Department of Pharmaceutics, MAEER’S Maharashtra Institute of Pharmacy, S. No. 124, MIT Campus, Paud Road, Kothrud, Pune 411038, Maharashtra, India
  • SWAPNIL SHETE Department of Pharmaceutics, MAEER’S Maharashtra Institute of Pharmacy, S. No. 124, MIT Campus, Paud Road, Kothrud, Pune 411038, Maharashtra, India

Abstract

Objective: Co-crystal is defined as a crystalline complex of two or more neutral molecules bound together primarily by hydrogen bonding or other non-covalent interactions. The pharmaceutical co-crystal involves crystal lattice arrangement between an Active Pharmaceutical Ingredient (API) with another pharmaceutically acceptable molecule. Co-crystals of API are preferred since they depict improved solubility, dissolution, stability, compressibility in comparison with API. Ibuprofen lysine (IL), frequently used analgesic and the anti-inflammatory drug has poor aqueous solubility and compressibility. This work shows the feasibility and optimal conditions for the preparation of co-crystals of ibuprofen lysine using Polyvivylpyrrolidone K25 (PK 25) and Polyvivylpyrrolidone K30 (PK 30) as co-formers.


Methods: In this study, we prepared and studied the solubility, drug content, flow properties, physical stability of novel co-crystal, consisting of IL and PK 25/PK 30. The co-crystal IL: PK 30 (at a molar ratio of 0.29:0.5) and IL: PK 25 (at a molar ratio of 0.58:1) were characterized by X-ray analysis, infrared spectroscopy and thermal analysis. Furthermore, the tablet formulations of the co-crystals were subjected to in vitro dissolution and in vivo analgesic activity, with the goal of comparing the co-crystals with IL and the marketed tablet of ibuprofen (Brufen®) respectively.


Results: The IL: PK co-crystals demonstrated superior solubility and the dissolution properties over IL. The compression properties of the co-crystals were similar to IL. The co-crystals exhibited higher analgesic activity than the marketed tablet. 


Conclusion: The results indicated the use of PK 25 and PK 30 as safe and promising co-crystal formers.

Keywords: Ibuprofen, Co-crystal, Polyvinylpyrrolidone, Solubility, Non-covalent, Analgesic

References

1. Gruber P. Solubilized ibuprofen. EP1863460A2; 2013. Available from: www.google.com.ar/patents/ [Last accessed on 15 Oct 2019]
2. Nerurkar J, Beach JW, Park MO, Jun HW. Solubility of (±)-ibuprofen and S (+)-ibuprofen in the presence of cosolvents and cyclodextrins. Pharm Dev Techonol 2005;10:413–21.
3. Zalte AG, Darekar AB, Gondkar SB, Saudagar RB. Preparation and characterization of ibuprofen co-crystals by using the solvent grinding method. World J Pharm Res 2014;3:1392–402.
4. Trask AV, Sam Motherwell WD, Jones W. Physical stability enhancement of theophylline via cocrystallization. Int J Pharm 2006;320:114–23.
5. Desiraju GR. Crystal and co-crystal. Cryst Eng Comm 2003;5:466-7.
6. Aakeroy CB, Desper J, Helfrich BA. Heteromeric intermolecular interactions as synthetic tools for the formation of binary co-crystals. Cryst Eng Comm 2004;6:19-24.
7. Karki S, Friscic T, Fabian L, Laity PR, Day GM, Jones W. Improving mechanical properties of crystalline solids by co-crystal formation: new compressible forms of paracetamol. Adv Mater 2009;21:3905-9.
8. Lemmerer A, Esterhuyesn C, Bernstein J. Synthesis, characterization and molecular modeling of a pharmaceutical co-crystal: (2-chloro-4-Nirtrobezoic Acid): (nicotinamide). J Pharm Sci 2010;99:4054-71.
9. Bohler V. Kollidon polyvinylpyrrolidone for the pharmaceutical industry. BASF The Chemical Industry. 4th ed. Ludwigshafen, Germany: BASF; 1998.
10. Rowe RC, Sheskey PJ, Owen SC. editors. Handbook of pharmaceutical excipients. 5th ed. London, UK: Pharmaceutical Press; 2005.
11. Merck MJ, O’Neil M, Smith A, Heckelman PE, Budavari S. editors. The Merck Index: An Encyclopedia of chemicals, drugs, and biologicals. 13th ed. New Jersey: Merck Research Laboratories Division of MERCK and CO; 2001.
12. Savant DA. editor. The Pharmaceutical Science, Pharma Pathway Pure Applied Pharmacy. 1st ed. Pune: Nirali Prakashan; 2016.
13. Government of India Ministry of Health and Family Welfare, editor. In Indian Pharmacopoeia. Vol. I. and Vol. II. 6th ed. Ghaziabad: Indian Pharmacopoeia Commission; 2010.
14. University of the Sciences in Philadelphia, editor. Remington: The Science and Practice of Pharmacy. Vol. I. 21st ed. Philadelphia: Lippincott Williams and Wilkins; 2005.
15. United States Pharmacopoeia, editor. USP/NF 2004 (USP 27/NF22). Maryland, USA: United States Pharmacopoeial Convention; 2004.
16. Pharmaceuticals and Medical Devices Agency. editor. The Japanese Pharmacopoeia. 16th ed. Tokyo: Pharmaceuticals and Medical Devices Agency; 2011.
17. Sharma HL, Sharma KK. editors. Principles of Pharmacology. 1st ed. New Delhi: Paras Medical Publishers; 2007.
18. Chow SF, Chen M, Shi L, Chow AH, Sun CC. Simultaneously improving the mechanical properties, dissolution performance, and hygroscopicity of ibuprofen and flurbiprofen by cocrystallization with nicotinamide. Pharm Res 2012;29:1854-65.
19. Soares FLF, Carneiro RL. Green synthesis of ibuprofen–nicotinamide cocrystals and in-line evaluation by Raman spectroscopy. Cryst Growth Des 2013;13:1510–7.
20. Alshahateet SF. Synthesis and X-ray crystallographic analysis of pharmaceutical model Rac-ibuprofen cocrystal. J Chem Crystallogr 2011;41:276–9.
21. Jagadeesh Babu N, Shreeniwas LR, Nangia A. Amide? N-Oxide heterosynthon and amide dimer homosynthon in cocrystals of carboxamide drugs and pyridine N–oxides. Mol Pharmaceutics 2007;4:417-34.
22. Acids and bases: molecular structure and acidity. Available from: http://www.chem.ucla.edu/~harding/tutorials/acids_and_bases/mol_str.pdf. [Last accessed on 15 Oct 2019]
23. Hickey MB, Peterson ML, Scoppettuolo LA, Morrisette SL, Vetter A, Guzman H, et al. Performance comparison of a co-crystal of carbamazepine with marketed product. Eur J Pharm Biopharm 2007;67:112–9.
Statistics
74 Views | 38 Downloads
Citatons
How to Cite
KULKARNI, A., BACHHAV, R., HOL, V., & SHETE, S. (2020). CO-CRYSTALS OF ACTIVE PHARMACEUTICAL INGREDIENT-IBUPROFEN LYSINE. International Journal of Applied Pharmaceutics, 12(3), 22-32. https://doi.org/10.22159/ijap.2020v12i3.36463
Section
Original Article(s)